Patient characteristics
| . | . | Year of first ASCT . | |||||
|---|---|---|---|---|---|---|---|
| . | All patients . | <1997 . | 1998-2003 . | 2004-2008 . | 2009-2013 . | ≥2014 . | P* . |
| Sample size | 4329 | 661 | 1002 | 1294 | 837 | 535 | |
| Median follow-up time [range], y | 10.5 [0.01-26.4] | 21.5 [0.02-26.4] | 15.3 [0.01-20.0] | 11.0 [0.01-14.6] | 6.5 [0.02-9.5] | 2.5 [0.01-4.5] | — |
| Age, y | <.0001 | ||||||
| Median [range] | 58.9 [17.4-84.8] | 53.0 [27.1-77.0] | 57.4 [25.1-84.8] | 59.7 [30.3-84.5] | 61.7 [17.4-82.5] | 63.0 [32.9-79.3] | |
| <65 | 3123 (72.1) | 599 (90.6) | 773 (77.2) | 910 (70.3) | 533 (63.7) | 308 (57.6) | |
| ≥65 | 1206 (27.9) | 62 (9.4) | 229 (22.9) | 384 (29.7) | 304 (36.3) | 227 (42.4) | |
| Sex | .88 | ||||||
| Male | 2646 (61.1) | 399 (60.4) | 620 (61.9) | 800 (61.8) | 507 (60.6) | 320 (59.8) | |
| Female | 1683 (38.9) | 262 (39.6) | 382 (38.1) | 494 (38.2) | 330 (39.4) | 215 (40.2) | |
| Race/ethnicity | <.0001 | ||||||
| White | 3723 (86.0) | 610 (92.3) | 894 (98.2) | 1108 (85.6) | 680 (81.2) | 431 (80.6) | |
| African American | 440 (10.2) | 40 (6.1) | 81 (8.1) | 128 (9.9) | 117 (13.8) | 74 (13.8) | |
| Other | 166 (3.8) | 11 (1.7) | 27 (2.7) | 58 (4.5) | 40 (4.8) | 30 (5.6) | |
| On a TT clinical trial | <.0001 | ||||||
| Yes | 1861 (43.0) | 204 (30.9) | 517 (51.6) | 558 (43.1) | 463 (55.3) | 119 (22.2) | |
| No | 2468 (57.0) | 457 (69.1) | 485 (48.4) | 736 (56.9) | 374 (44.7) | 416 (77.8) | |
| TC6 classification | <.0001 | ||||||
| CCND1 | 434 (10.0) | 0 (0.0) | 33 (3.3) | 175 (13.4) | 150 (17.9) | 76 (14.2) | |
| CCND3 | 43 (1.0) | 0 (0.0) | 5 (0.5) | 12 (0.9) | 19 (2.3) | 7 (1.3) | |
| D1 | 650 (15.0) | 0 (0.0) | 56 (5.6) | 255 (19.7) | 221 (26.4) | 118 (22.1) | |
| D2 | 605 (14.0) | 0 (0.0) | 48 (4.8) | 246 (19.0) | 192 (22.2) | 119 (22.2) | |
| MAF/MAFB | 157 (3.6) | 0 (0.0) | 6 (0.6) | 69 (5.3) | 44 (5.3) | 38 (7.1) | |
| MMSET | 274 (6.3) | 0 (0.0) | 29 (2.9) | 112 (8.7) | 92 (11.0) | 41 (7.7) | |
| No data | 2166 (50.0) | 661 (100) | 825 (82.3) | 425 (32.8) | 119 (14.2) | 136 (25.4) | |
| GEP70 | <.0001 | ||||||
| Low risk | 1838 (42.5) | 0 (0.0) | 230 (23.0) | 706 (54.6) | 591 (70.6) | 311 (58.1) | |
| High risk | 397 (9.2) | 0 (0.0) | 33 (3.3) | 170 (13.1) | 124 (14.8) | 71 (13.3) | |
| No data | 2093 (48.3) | 661 (100) | 739 (73.8) | 418 (32.3) | 122 (14.6) | 153 (28.6) | |
| Any chromosomal abnormality | <.0001 | ||||||
| Yes | 1641 (37.9) | 451 (68.2) | 630 (62.9) | 834 (64.5) | 440 (52.6) | 288 (53.8) | |
| No | 2643 (61.1) | 189 (28.6) | 361 (36.0) | 451 (34.9) | 394 (47.1) | 246 (46.0) | |
| No data | 45 (1.0) | 21 (3.2) | 11 (1.1) | 9 (0.7) | 3 (0.4) | 1 (0.2) | |
| Tandem transplant | <.0001 | ||||||
| No | 1648 (38.1) | 247 (37.4) | 392 (39.1) | 335 (25.9) | 386 (46.1) | 288 (53.8) | |
| Yes | 2681 (61.9) | 414 (62.6) | 610 (60.9) | 959 (74.1) | 451 (53.9) | 247 (46.2) | |
| ISS† | <.0001 | ||||||
| I | 1844 (42.6) | 290 (43.9) | 542 (54.1) | 523 (40.4) | 270 (32.3) | 191 (39.0) | |
| II | 1453 (33.6) | 187 (28.3) | 261 (26.1) | 487 (37.6) | 340 (40.6) | 167 (34.1) | |
| III | 792 (18.3) | 73 (11.0) | 186 (18.6) | 263 (20.3) | 204 (24.4) | 60 (12.2) | |
| No data | 240 (5.5) | 111 (16.8) | 13 (1.3) | 21 (1.6) | 21 (1.6) | 72 (14.7) | |
| . | . | Year of first ASCT . | |||||
|---|---|---|---|---|---|---|---|
| . | All patients . | <1997 . | 1998-2003 . | 2004-2008 . | 2009-2013 . | ≥2014 . | P* . |
| Sample size | 4329 | 661 | 1002 | 1294 | 837 | 535 | |
| Median follow-up time [range], y | 10.5 [0.01-26.4] | 21.5 [0.02-26.4] | 15.3 [0.01-20.0] | 11.0 [0.01-14.6] | 6.5 [0.02-9.5] | 2.5 [0.01-4.5] | — |
| Age, y | <.0001 | ||||||
| Median [range] | 58.9 [17.4-84.8] | 53.0 [27.1-77.0] | 57.4 [25.1-84.8] | 59.7 [30.3-84.5] | 61.7 [17.4-82.5] | 63.0 [32.9-79.3] | |
| <65 | 3123 (72.1) | 599 (90.6) | 773 (77.2) | 910 (70.3) | 533 (63.7) | 308 (57.6) | |
| ≥65 | 1206 (27.9) | 62 (9.4) | 229 (22.9) | 384 (29.7) | 304 (36.3) | 227 (42.4) | |
| Sex | .88 | ||||||
| Male | 2646 (61.1) | 399 (60.4) | 620 (61.9) | 800 (61.8) | 507 (60.6) | 320 (59.8) | |
| Female | 1683 (38.9) | 262 (39.6) | 382 (38.1) | 494 (38.2) | 330 (39.4) | 215 (40.2) | |
| Race/ethnicity | <.0001 | ||||||
| White | 3723 (86.0) | 610 (92.3) | 894 (98.2) | 1108 (85.6) | 680 (81.2) | 431 (80.6) | |
| African American | 440 (10.2) | 40 (6.1) | 81 (8.1) | 128 (9.9) | 117 (13.8) | 74 (13.8) | |
| Other | 166 (3.8) | 11 (1.7) | 27 (2.7) | 58 (4.5) | 40 (4.8) | 30 (5.6) | |
| On a TT clinical trial | <.0001 | ||||||
| Yes | 1861 (43.0) | 204 (30.9) | 517 (51.6) | 558 (43.1) | 463 (55.3) | 119 (22.2) | |
| No | 2468 (57.0) | 457 (69.1) | 485 (48.4) | 736 (56.9) | 374 (44.7) | 416 (77.8) | |
| TC6 classification | <.0001 | ||||||
| CCND1 | 434 (10.0) | 0 (0.0) | 33 (3.3) | 175 (13.4) | 150 (17.9) | 76 (14.2) | |
| CCND3 | 43 (1.0) | 0 (0.0) | 5 (0.5) | 12 (0.9) | 19 (2.3) | 7 (1.3) | |
| D1 | 650 (15.0) | 0 (0.0) | 56 (5.6) | 255 (19.7) | 221 (26.4) | 118 (22.1) | |
| D2 | 605 (14.0) | 0 (0.0) | 48 (4.8) | 246 (19.0) | 192 (22.2) | 119 (22.2) | |
| MAF/MAFB | 157 (3.6) | 0 (0.0) | 6 (0.6) | 69 (5.3) | 44 (5.3) | 38 (7.1) | |
| MMSET | 274 (6.3) | 0 (0.0) | 29 (2.9) | 112 (8.7) | 92 (11.0) | 41 (7.7) | |
| No data | 2166 (50.0) | 661 (100) | 825 (82.3) | 425 (32.8) | 119 (14.2) | 136 (25.4) | |
| GEP70 | <.0001 | ||||||
| Low risk | 1838 (42.5) | 0 (0.0) | 230 (23.0) | 706 (54.6) | 591 (70.6) | 311 (58.1) | |
| High risk | 397 (9.2) | 0 (0.0) | 33 (3.3) | 170 (13.1) | 124 (14.8) | 71 (13.3) | |
| No data | 2093 (48.3) | 661 (100) | 739 (73.8) | 418 (32.3) | 122 (14.6) | 153 (28.6) | |
| Any chromosomal abnormality | <.0001 | ||||||
| Yes | 1641 (37.9) | 451 (68.2) | 630 (62.9) | 834 (64.5) | 440 (52.6) | 288 (53.8) | |
| No | 2643 (61.1) | 189 (28.6) | 361 (36.0) | 451 (34.9) | 394 (47.1) | 246 (46.0) | |
| No data | 45 (1.0) | 21 (3.2) | 11 (1.1) | 9 (0.7) | 3 (0.4) | 1 (0.2) | |
| Tandem transplant | <.0001 | ||||||
| No | 1648 (38.1) | 247 (37.4) | 392 (39.1) | 335 (25.9) | 386 (46.1) | 288 (53.8) | |
| Yes | 2681 (61.9) | 414 (62.6) | 610 (60.9) | 959 (74.1) | 451 (53.9) | 247 (46.2) | |
| ISS† | <.0001 | ||||||
| I | 1844 (42.6) | 290 (43.9) | 542 (54.1) | 523 (40.4) | 270 (32.3) | 191 (39.0) | |
| II | 1453 (33.6) | 187 (28.3) | 261 (26.1) | 487 (37.6) | 340 (40.6) | 167 (34.1) | |
| III | 792 (18.3) | 73 (11.0) | 186 (18.6) | 263 (20.3) | 204 (24.4) | 60 (12.2) | |
| No data | 240 (5.5) | 111 (16.8) | 13 (1.3) | 21 (1.6) | 21 (1.6) | 72 (14.7) | |
Unless otherwise indicated, values are n (%).
P value from Kruskal-Wallis 1-way analysis of variance test (for comparing medians of continuous variables) and χ2 test (for comparing proportions of categorical variables).
For TT patients, ISS is based on the most recent albumin and β2-M measurement taken between study enrollment and induction therapy. For non-TT patients, ISS is based on the most recent albumin and β2-M measurement taken before the date of the first ASCT.